



Aline J. Charabaty

Pishvaian, MD

Associate Professor of Clinical Medicine,
Clinical Director of Gastroenterology and
Director of the Inflammatory Bowel Disease Center
at Sibley Memorial Hospital
Washington, D.C.

EMPOWERING PATIENTS, ELEVATING CARE: IMPROVING CULTURAL COMPETENCY IN INFLAMMATORY BOWEL DISEASE (IBD) CARE

Program Overview

Despite the availability of evidence-based guidelines, IBD is still diagnosed late, managed inconsistently, and impacted by persistent disparities—particularly among underserved populations. These challenges lead to delayed remission, increased complications, and inequitable outcomes.

This free, CME-certified, case-based session offers an innovative, hands-on learning experience through:

- ✓ Expert-led presentation on the latest therapeutic strategies and health equity in IBD care
- ✓ Case-based insights reflecting diverse patient scenarios
- ✓ AI-powered patient simulation workshop with interactive avatars, real-time feedback, and performance tracking to enhance diagnostic, treatment, and communication skills

Led by expert faculty, **Aline J. Charabaty Pishvaian, MD**, and developed in partnership with the **Color of Gastrointestinal Illness (COGI)**, the program focuses on:

- Early, accurate diagnosis across diverse populations
- Evidence-based use of emerging IBD therapies
- Treat-to-target strategies with biomarker monitoring
- Culturally competent communication to improve adherence and outcomes

Target Audience

The intended audience for this activity is gastroenterology fellows, gastroenterologists, internists, nurse practitioners, and physician assistants involved in the management of patients with IBD

FRI, OCT 29

6:00PM - 7:30PM ET

Register early — space is limited.

Learn more by scanning the

QR code or visiting:

bit.ly/ibd-dc



Learning Objectives

Upon completion of this activity, the participant should be able to:

- **Apply** evidence-based diagnostic criteria to identify IBD and its complications in diverse patient populations, including atypical presentations in underserved communities.
- **Demonstrate** improved competency in selecting of new and emerging IBD therapies with consideration of patient-specific factors.
- **Outline** personalized treatment plans that integrate new therapeutic options and biomarker monitoring.
- **Describe** strategies for integrating precision medicine tools into personalized IBD treatment plans.
- **Integrate** culturally competent care strategies into treat-to-target approaches to improve IBD patient outcomes including patients with social and economic barriers.
- **Demonstrate** effective communication strategies that consider diverse backgrounds, beliefs, and preferences.

EARN UP TO 1.25 AMA PRA CATEGORY 1 CREDIT™

This live CME session is jointly provided by:



In partnership with:



This educational activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc..